Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib

AIM: Fixed dose oral tyrosine kinase inhibitors imatinib, sunitinib and pazopanib show a high interpatient variability in plasma exposure. A relationship between plasma exposure and treatment outcome has been established, which supports the rationale for dose optimization of these drugs. The aim of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Br J Clin Pharmacol
Main Authors: Lankheet, Nienke A. G., Desar, Ingrid M. E., Mulder, Sasja F., Burger, David M., Kweekel, Dinemarie M., van Herpen, Carla M. L., van der Graaf, Winette T. A., van Erp, Nielka P.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Pharmacokinetics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5595974/
https://ncbi.nlm.nih.gov/pubmed/28500677
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13327
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados